Evaluation of European severe acute respiratory infection (SARI) surveillance, 27 European countries, 2022/23
- PMID: 40406887
- PMCID: PMC12105088
- DOI: 10.2807/1560-7917.ES.2025.30.20.2400655
Evaluation of European severe acute respiratory infection (SARI) surveillance, 27 European countries, 2022/23
Abstract
BackgroundBetween 2020 and 2023, ECDC has supported 21 of 30 EU/EEA and six Western Balkan countries by enhancing severe acute respiratory infection (SARI) surveillance to monitor trends, detect unexpected events, evaluate public health interventions, identify risk factors and support vaccine effectiveness studies. Using diverse strategies, countries have implemented SARI surveillance and reported data at national/European levels.AimWe evaluated European-level SARI surveillance and provided recommendations to achieve objectives and improve key attribute performance.MethodsWe analysed 2022/23 surveillance data for completeness. We administered a questionnaire, targeting country-level representatives, to evaluate surveillance attributes (meeting objectives, usefulness, acceptability, timeliness, representativeness) and identify strengths, weaknesses, opportunities and threats.ResultsThirteen countries (13/27) reported data at European level. Data showed good overall completeness but varied across countries and some variables need improvement (vaccination, sequencing). The questionnaire was completed by all 27 countries. Most countries (23/27) reported that the system effectively monitored trends and considered it useful and acceptable (25/27), but only 16 found it timely and 14 representative. Challenges included insufficient case-based data, data linkage issues and insufficient data completeness. Slow/inefficient manual data extraction affected timeliness, while insufficient geographical coverage affected representativeness. Multi-pathogen surveillance was identified as the main strength, heterogeneity of systems the main weakness, improvements of hospital information systems the main opportunity, and lack of sustainable funding the main threat.ConclusionsSARI surveillance was perceived as effective in monitoring trends, useful and acceptable. To achieve additional objectives and enhance timeliness and representativeness, we recommend improving data completeness, digitalisation/automation and geographical coverage.
Keywords: SARS-CoV-2; evaluation; influenza; respiratory syncytial virus (RSV); severe acute respiratory infection (SARI); surveillance.
Conflict of interest statement
References
-
- Ziemann A, Rosenkötter N, Riesgo LGC, Fischer M, Krämer A, Lippert FK, et al. Meeting the International Health Regulations (2005) surveillance core capacity requirements at the subnational level in Europe: the added value of syndromic surveillance. BMC Public Health. 2015;15(1):107. 10.1186/s12889-015-1421-2 - DOI - PMC - PubMed
-
- Tolksdorf K, Haas W, Schuler E, Wieler LH, Schilling J, Hamouda O, et al. ICD-10 based syndromic surveillance enables robust estimation of burden of severe COVID-19 requiring hospitalization and intensive care treatment. medRxiv; 2022. Preprint. https://www.medrxiv.org/content/10.1101/2022.02.11.22269594v2 10.1101/2022.02.11.22269594 - DOI - DOI
-
- World Health Organization (WHO). Global epidemiological surveillance standards for influenza. Geneva: WHO; 2013. Available from: https://apps.who.int/iris/handle/10665/311268
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous